Search

Helpdesk

Sales contact

Home > Resources > Insights from Kayentis clients: why you should choose Kayentis as your eCOA & DCT provider

Insights from Kayentis clients: why you should choose Kayentis as your eCOA & DCT provider

Project management

Last updated: July 3, 2024

Responsiveness, reliability, professionalism, friendliness… discover why 95.6% of Kayentis clients recommend Kayentis in 2023!

Challenge your eCOA & DCT provider: choose Kayentis for your next clinical trial!

Follow us on social media

Subscribe to our newsletter

You may also like

Advancing oncology research: the crucial role of patient-reported outcomes in...

6 Best Practices for Accelerating eCOA Study Start-Up Timelines

How Kayentis Delivered eCOA Go-Live in Just 5 Weeks for...

Turning endpoint noise into reliable CNS trial data

Kayentis publishes its first ESG report, strengthening its commitment to...

Kayentis launches interactive eConsent solution to simplify and improve patient...

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Meet us at the following events

CTAD Clinical Trial on Alzheimer’s Disesases

16-19 NOV 2026 • Boston, MA, USA

Meet our colleague Anna Dudalyan at CTAD. Schedule a meeting